|
Repros Revises Indication for Androxal
At the FDA’s request, Repros Therapeutics has submitted a revised indication to investigate Androxal oral tablets as a low-testosterone treatment for hypogonadal men.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives